Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes

Aims  To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus and triglycerides ≤ 6.0 mmol/l. Methods  A double‐blind, randomized, multicentre study to assess the effect of rosuvastatin and atorvastatin,...

Full description

Saved in:
Bibliographic Details
Published in:Diabetic medicine 2007-05, Vol.24 (5), p.541-549
Main Authors: Betteridge, D. J., Gibson, J. M.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
atorvastatin
Atorvastatin Calcium
Biological and medical sciences
Cholesterol, LDL - blood
Cholesterol, LDL - drug effects
Diabetes Mellitus, Type 2 - drug therapy
Diabetes. Impaired glucose tolerance
Double-Blind Method
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Fluorobenzenes - therapeutic use
Heptanoic Acids - therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
lipids
Lipids - blood
Lipoproteins - blood
Lipoproteins - drug effects
low-density lipoprotein cholesterol
Male
Medical sciences
Middle Aged
Pyrimidines - therapeutic use
Pyrroles - therapeutic use
rosuvastatin
Rosuvastatin Calcium
Sulfonamides - therapeutic use
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims  To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus and triglycerides ≤ 6.0 mmol/l. Methods  A double‐blind, randomized, multicentre study to assess the effect of rosuvastatin and atorvastatin, at 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks, on low‐density lipoprotein cholesterol (LDL‐C), together with a range of secondary lipid and lipoprotein end points. Results  Rosuvastatin reduced mean LDL‐C levels from baseline over 16 weeks by 57.4%, while atorvastatin reduced mean LDL‐C levels by 46.0% over the same period. The difference in LDL‐C reduction between treatments was statistically significant (P 
ISSN:0742-3071
1464-5491
DOI:10.1111/j.1464-5491.2007.02095.x